Allogene Therapeutics

Allogene is working to overcome the limitations of autologous CAR T therapies by creating allogeneic CAR T cell therapies, or AlloCAR T™ therapies. Unlike autologous cell therapy, AlloCAR T™ therapy uses T cells from healthy donors.

These cells are isolated in a manufacturing facility, engineered to express CARs to recognize and destroy cancer cells, and modified via gene editing to limit autoimmune response when given to a patient. These therapies are then stored for off-the-shelf use on demand. We believe that, at scale, a single manufacturing run has the potential to yield treatment for 100+ patients.

Allogenic CAR T Cell Therapy

The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing andadvanced proprietary cell manufacturing technologies.

Clinical trials

The company is currently running five clinical-stage programs of AlloCAR TTM therapies for cancer:

1. ALLO-501 (The ALPHA Trial: Relapsed or refractory non-Hodgkin lymphoma),

2. ALLO-501A (The ALPHA2 Trial: Relapsed or refractory non-Hodgkin lymphoma),

3. ALLO-715 and ALLO-715 + nirogascestat (The UNIVERSAL Trial: Relapsed or refractory multiple myeloma),

4. ALLO-316 (TRAVERSE Study: Renal Cell Carcinoma),

5. ALLO-605 (The IGNITE Study: Relapsed or refractory multiple myeloma).

How it works

The process for manufacturing our investigational off-the-shelf AlloCAR TTM therapy begins by harvesting healthy, selected, screened and tested T cells from healthy donors. The benefit of starting with healthy donors is that a larger portion of eligible patients, including those who are critically ill and lack a robust supply of T cells for harvest and expansion, can potentially receive treatment.

Additionally, with our platform no patient needs to undergo leukapheresis (a laboratory procedure in which a patient’s white blood cells are separated and the remaining blood cells and plasma are returned to the patient).

Next, the T cells are engineered to express CARs, which recognize certain cell-surface proteins that are expressed in hematologic or solid tumors. For example, ALLO-501 and ALLO-501A, two of our investigational therapies, recognize CD19, a cell-surface protein expressed on B-cells, including cancerous B-cells; they are just the first in a line of AlloCAR TTM therapies we plan to develop. The next step in the process involves gene editing to reduce the risk of graft-vs-host disease (GVHD) and allogeneic rejection. A T cell receptor gene is knocked out to avoid GVHD. The CD52 gene is knocked out to render the CAR T product resistant to anti-CD52 antibody treatment. ALLO-647, our proprietary investigational anti-CD52 monoclonal antibody, is designed to suppress the host immune system and allow the AlloCAR TTM therapy to stay engrafted in order to achieve full therapeutic impact.

The engineered T cells then undergo a purification step and are ultimately cryopreserved in vials for delivery to patients.

SpringWorks Therapeutics

SpringWorks Therapeutics

Allogene Therapeutics, Inc. is creating AlloCAR T™ PLATFORM for multiplex gene-engineering and gene-editing capabilities.

About 275 employees singularly focused on the development of AlloCAR T™ therapy.

Allogene Therapeutics, Inc. (Nasdaq) Allo is a public company, which was founded 2017 in San Francisco, USA and is developing AlloCAR T™ therapies for cancer.

Clinical trials

The company is currently running five clinical-stage programs of AlloCAR T™ therapies for cancer:

1. ALLO-501 (The ALPHA Trial: Relapsed or refractory non-Hodgkin lymphoma),

2. ALLO-501A (The ALPHA2 Trial: Relapsed or refractory non-Hodgkin lymphoma),

3. ALLO-715 and ALLO-715 + nirogascestat (The UNIVERSAL Trial: Relapsed or refractory multiple myeloma),

4. ALLO-316 (TRAVERSE Study: Renal Cell Carcinoma),

5. ALLO-605 (The IGNITE Study: Relapsed or refractory multiple myeloma).

Partnerships:

Pfizer + Celectis:

"We assumed Pfizer’s strategic collaboration and licensing agreement with Cellectis, with exclusive rights to develop and commercialize previously defined allogeneic CAR T therapy programs directed at select targets."

Notch Therapeutics

In collaboration and under license agreement with Notch Therapeutics the company is researching and developing induced pluripotent stem cell (iPSC) AlloCAR™ therapy products for initial application in non-Hodgkin lymphoma, leukemia and multiple myeloma.

Servier group

In collaboration with Servier is developing for UCART19, for the treatment of adult and pediatric acute lymphoblastic leukemia (ALL).

SpringWorks Therapeutics

In collaboration is developing ALLO-715, a investigational anti-B-cell maturation antigen (BCMA) AlloCAR T™ therapy in combination with SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, for patients with relapsed or refractory multiple myeloma.